Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.5 (EPT/RI) Astrazeneca PLC

7 May 2014 10:30

RNS Number : 4567G
Morgan Stanley Capital Services LLC
07 May 2014
Β 

ο»Ώ

Β 

Β FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Β 

ASTRAZENECA PLC

(d) Date dealing undertaken:

06 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES

Β 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Β 

(a) Purchases and sales

Β 

Β Class of relevant security

Β Purchases/sales

Β Total number of securities

Β Highest price per unit paid/received

Β Lowest price per unit paid/received

Β ADRS

Β PURCHASES

Β 222,310(Traded in ADR form)

Β 79.5100 USD

Β 78.9100 USD

Β ADRS

Β SALES

Β 1,600(Traded in ADR form)

Β 79.3900 USD

Β 79.0800 USD

Β 

Β 

(b) Derivatives transactions (other than options)

Β 

Β Class of relevant security

Β Product description

e.g. CFD

Β Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Β Number of reference securities

Β Price per unit

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 36

Β 47.1841 GBP

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 47

Β 47.1841 GBP

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 6,000

Β 47.2565 GBP

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 121

Β 47.3500 GBP

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 918

Β 47.4390 GBP

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 196

Β 47.4390 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 40,257

Β 46.7109 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 21,483

Β 46.7109 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 20,300

Β 46.7109 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 1,260

Β 46.7109 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 20,000

Β 46.7532 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 4,174

Β 46.8948 GBP

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 196

Β 47.3500 GBP

Β USD 0.25 ORDINARY

Β CFD

Β LONG

Β 2,500

Β 517.0000 SEK

Β USD 0.25 ORDINARY

Β CFD

Β SHORT

Β 1,597

Β 522.1058 SEK

Β ADRS

Β CFD

LONG

Β 1,100 (Traded in ADR form)

Β 79.3327 USD

Β ADRS

Β CFD

SHORT

Β 100 (Traded in ADR form)

Β 78.9100 USD

Β ADRS

Β CFD

SHORT

Β 224 (Traded in ADR form)

Β 79.1251 USD

Β ADRS

Β CFD

SHORT

Β 169 (Traded in ADR form)

Β 79.1251 USD

Β 

Β 

(c) Options transactions in respect of existing securities

Β 

(i) Writing, selling, purchasing or varying

Β 

Β Class of relevant security

Β Product description e.g. call option

Β Writing, purchasing, selling, varying etc.

Β Number of securities to which option relates

Β Exercise price per unit

Β Type e.g. American, European etc.

Β Expiry date

Β Option money paid/ received per unit

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β 

(ii) Exercising

Β 

Β Class of relevant security

Β Product description e.g. call option

Β Number of securities

Β Exercise price per unit

Β N/A

Β N/A

Β N/A

Β N/A

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Β Class of relevant security

Β Nature of dealing e.g. subscription, conversion

Β Details

Β Price per unit (if applicable)

Β N/A

Β N/A

Β N/A

Β N/A

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

Β 

Β 

3. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

Β 

Β 

Date of disclosure:

07 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
FERUBUKRSOAVRRR
Date   Source Headline
7th May 201411:20 amBUSForm 8.3 - Pfizer Inc
7th May 201410:40 amRNSForm 8.5 (EPT/RI) astrazeneca PLC
7th May 201410:38 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:36 amRNSForm 8.5 (EPT/RI) Pfizer INC
7th May 201410:31 amRNSRule 2.10 Announcement
7th May 201410:30 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:29 amRNSForm 8.5 (EPT/RI) Pfizer Inc
7th May 20147:00 amRNSBENEFITS OF A COMBINATION WITH ASTRAZENECA
7th May 20147:00 amRNSForm 8.5 (EPT/NON-RI)
6th May 20146:16 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
6th May 20146:08 pmRNSForm 8.5 (EPT/NON-RI)(OPD)
6th May 20145:15 pmRNSForm 8 (DD) - Pfizer Inc.
6th May 20144:46 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:42 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:16 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:14 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:11 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:07 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:05 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:04 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:02 pmBUSForm 8.3 - PFIZER INC
6th May 20143:56 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:53 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:49 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:46 pmRNSForm 8.5 (EPT/RI)replacement - Astrazeneca PLC
6th May 20143:34 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:23 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:18 pmRNSForm 8.3 - astrazeneca plc
6th May 20143:16 pmRNSForm 8.3 - PFIZER INC
6th May 20143:15 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20143:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20143:00 pmRNSForm 8.3 - Pfizer Inc.
6th May 20142:51 pmRNSForm 8.3 - [PFIZER INC]
6th May 20142:48 pmBUSForm 8.3 - Pfizer Inc
6th May 20142:31 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
6th May 20141:54 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:48 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:28 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:25 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:20 pmRNSForm 8.3 - [AstraZeneca Plc]
6th May 20141:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:13 pmRNSForm 8.5 (EPT/RI)
6th May 20141:09 pmRNSForm 8.5 (EPT/NON-RI)
6th May 20141:07 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:06 pmRNSForm 8.5 (EPT/RI)
6th May 201412:35 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.